Risk assessment ofxenobiotics using animal data involves extrapolation from high doses to low ones, and from animal species to humans. In some cases it also involves extrapolation from one route of exposure to another. To assess the risk of exposure to xenobiotics, information on both biokinetics and biodynamics are needed. The contribution of biokinetics to risk assessment is the subject of this review. The review includes the general aspects of biokinetics of chemicals, the models available to describe the biokinetic behaviour of a chemical and a discussion of the class of biokinetic models that is considered most suited for application to risk assessment: the physiologi cally-based biokinetic (PBBK) models. The power of PBBK models is illustrated with a few examples.
Calabrese EJGastrointestinal and dermal absorption: interspecies differences. Drug Metabolism Reviews1984; 15: 1013 - 32.
2.
Gerrity TR, Henry CJ. (eds). Principles of route-to-route extrapolation for risk assessment. New York, Elsevier1990.
3.
Lippmann M., Yeates DB, Albert REDeposition, retention, and clearance of inhaled particles. British Journal of Industrial Medicine1980 ; 37: 337-62.
4.
McClellan RO , Hesterberg TWRole of biopersistence in the pathogenicity of man-made fibers and methods for evaluating biopersistence. A summary of two round-table discussions. Proceedings of an IARC workshop on Biopersistence of respirable systhentic fibers and minerals , September 7 - 9, 1992,
5.
Lyon.Environmental Health Perspectives1994; 102: 277-83.
6.
Johanson G.Modelling of respiratory exchange of polar solvents. Annals of occupational Hygiene1991; 35: 323 - 39.
7.
Dahl ARContemporary issues in toxicology. Dose concepts for inhaled vapors and gases . Toxicology and Applied Pharmacology1990; 103: 185-97.
8.
Artursson P. , Karlsson J.Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (CACO-2) cells. Biochemical and Biophysical Research Communications1991; 175: 880-5.
9.
D'Souza RWModelling oral bioavailability: implication for risk assessment. In: Gerrity TR, Henry CJ. (eds). Principles of route-to-route extrapolation for risk assessment. New York , Elsevier, 1990; pp. 173 - 85.
10.
Fiserova-Bergerova V.Relevance of occupational skin exposure. Annals of occupational Hygiene1993; 37: 673 - 85.
11.
Flynn GLPhysicochemical determinants of skin absorption. In: Gerrity TR, Henry CJ. (eds). Principles of route-to-route extrapolation for risk assessment. New York, Elsevier, 1990; pp. 93- 129.
12.
Mattie DR, Grabau JH, McDougal JNSignificance of the dermal route of exposure to risk assessment. Risk Analysis1994; 14: 277-84.
13.
McDougal JN, Clewell HJ, Andersen ME, Jepson GWPhysiologically based pharmacokinetic modelling of skin penetration . In: Scott RC, Guy RH, Hadgraft J. (eds). Prediction of percutaneous penetration. London, IBC Technical Services, 1990.
14.
Fiserova-Bergerova V.Application of toxicokinetic models to establish biological exposure indicators. Annals of occupational Hygiene1990; 34: 639-51.
15.
Guy RH, Potts ROPenetration of industrial chemicals across the skin: A predictive model. American Journal of Industrial Medicine1993 ; 23: 711-9.
16.
Bronaugh RLMetabolism in skin. In: Gerrity TR, Henry CJ. (eds). Principles of route-to-route extrapolation for risk assessment . New York, Elsevier, 1990: pp. 185 - 91.
17.
Kao J., Patterson FK, Hall J.Skin penetration and metabolism of topically applied chemicals in six mammalian species, including man. An in vitro study with benzo(a)pyrene and testosterone . Toxicology and Applied Pharmacology1985; 81: 502-16.
18.
Farris FF, Dedrick RL, Allen PV, Smith JCPhysiological model for the pharmacokinetics of methyl mercury in the growing rat. Toxicology and Applied Pharmacology1993; 199: 74-90.
19.
Leggett RWAn age-specific kinetic model of lead metabolism in humans. Environmental Health Perspectives1993; 101: 598-616.
20.
Williams RTDetoxication mechanisms. Second edition. London, Chapman and Hall Ltd ., 1959 .
21.
Bond JAMetabolism of xenobiotics by the respiratory tract. In: Gardner DE, Crapo JD, McClellan RO. (eds). Toxicology of the lung. Second edition. Target organ toxicology series. (Hayes AW, Thomas JA, Gardner DE (Series eds)). New York, Raven Press, 1993; pp. 187-217.
22.
Gram TE. (ed). Extrahepatic metabolism of drugs and other foreign compounds. Lancaster, UK, MTP Press, 1980.
23.
Caldwell J.The current status of attempts to predict species differences in drug metabolism. Drug Metabolism Reviews1981; 12 : 221 - 37.
24.
Caldwell J.Conjugation reactions in foreign-compound metabolism: definition, consequences and species variations. Drug Metabolism Reviews1982; 13: 745 - 77.
Jensen AAChemical contaminants in human milk. Residue Review Vol 89. New York, Springer Verlag, 1983.
27.
Laug EP, Kunze FM, Prickett CSOccurrence of DDT in human fat and milk. Archives of Industrial Hygiene1951; 3: 245 - 6.
28.
Timbrell JAChapter 5: Factors affecting metabolism and disposition. In: Principles of biochemical toxicology. London, Taylor and Francis, 1985 ; pp. 88-90.
29.
Smith DAProblems and opportunities in toxicity testing arising from species differences in xenobiotic metabolism. Drug Metabolism Reviews1991; 23 (3-4): 355-73.
30.
Caldwell J.Species differences in metabolism and pharmacokinetics: are we close to an understanding?Toxicology Letters1992; 64-65: 651-9.
31.
Birnbaum LSPharmacokinetic basis of age-related changes in sensitivity of toxicants. Annual Review of Pharmacology1991; 31: 101-28.
32.
Rikans LEInfluence of aging on chemically induced hepatotoxicity: role of age-related changes in metabolism. Drug Metabolism Reviews1989; 20: 87-110.
33.
Burrows BM, Lebowitz MD, Camilli AE, Knudson RJLongitudinal changes in forced expiratory volume in one second in adults . American Review of Respiratory Disease1986; 133: 974-80.
34.
Varga F., Csakey Z.Changes in the blood supply of the gastrointestinal tract in rats with age. Pfluegers Archives. European Journal of Physiology1976; 364: 129 - 33.
35.
Wyss PA, Muehlebach S., Bickel MHPharmacokinetic of 2,2',4,4',5,5'hexachlorobiphenyl (6-CB) in rats with decreasing adipose tissue mass. I. Effects of restricting food intake two weeks after administration of 6-CB. Drug Metabolism and Disposition1982; 10 : 657-61.
36.
Birnbaum LSDistribution and excretion of 2,3,6,2',3',6'-and 2,4,5,2',4',5'-hexachlorobiphenyl in senescent rats. Toxicology and Applied Pharmacology1983; 70: 262-72.
37.
Andersen MEPhysiological modelling of organic compounds . Annals of Occupational Hygiene1991 ; 35: 309-21.
38.
Krishnan K. , Andersen MEPhysiologically based pharmacokinetic modeling in toxicology. In: Hayes AW (ed). Principles and Methods of Toxicologythird edition. New York, Raven Press Ltd., 1994 : pp. 149-88.
39.
Yang RS, Andersen MEPharmacokinetics. In: Hodgson E, Levi PE. (eds). Introduction to biochemical toxicology. Norwalk , Appleton and Lange, 1994; 49.
40.
Andersen ME , Krewski D., Withey JRPhysiological pharmacokinetics and cancer risk assessment. Cancer Letters1993 ; 69: 1-14.
41.
Evans MV, Crank WD, Yang HM, Simmons JEApplications of sensitivity analysis to a physiologically based pharmacokinetic model for carbon tetrachloride in rats. Toxicology and Applied Pharmacology1994; 128: 36-44.
42.
Hetrick DM, Jarabek AM, Travis CCSensitivity analysis for physiologically based pharmacokinetic models . Journal of Pharmacokinetics and Biopharmaceutics1991 ; 19: 1-20.
43.
Arms AD, Travis CCReference physiological parameters in pharmacokinetic modeling. Washington DC, US, EPA, 1988: Report Nr EPA/ 600/6-88/004.
44.
Delp MD, Manning RO, Bruckner JV, Armstrong RBDistribution of cardiac output during diurnal changes of activity in rats . American Journal of Physiology1991 ; 261: H1487-93.
45.
Dedrick RLAnimal scale-up. Journal of Pharmacokinetics and Biopharmaceutics1973; 1 : 435 - 61.
46.
Lindstedt SLAllometry: body size constraints in animal design. In: Pharmacokinetics in risk assessment: drinking water and health. Vol. 8. Workshop proceedings of Subcommittee on Pharmacokinetics in risk assessment, Safe drinking water committee, Board on Environmental Studies and Toxicology, Commission on Life Sciences, and National Research Council . Washington DC , National Academy Press, 1987; pp. 65 - 79.
47.
Stahl WRSimilarity and dimensional methods in biology. Science1962; 137 : 205-12.
48.
Travis CC, White RK, Wards RCInterspecies extrapolation of pharmacokinetics. Journal of Theoretical Biology1990; 142: 285 - 304.
49.
Fiserova-Bergerova V., Diaz MLDetermination and prediction of tissue-gas partition coefficients. International Archives of Occupational and Environmental Health1986; 58: 75-87.
50.
Gargas ML, Andersen MEPhysiologically based approaches for examining the pharmacokinetics of inhaled vapors. In: Gardner DE et al. (eds). Toxicology of the lung. First edition. Target organ toxicology series . New York, Raven Press, 1988; pp. 449-77.
51.
Gargas ML, Burgess RJ, Voisard DE, Cason GH, Andersen MEPartition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicology and Applied Pharmacology1989; 98 : 87-99.
52.
Gargas ML, Medinsky MA, Andersen MEAdvances in physiological modeling approaches for understanding the disposition of inhaled vapors. In: Gardner DE, Crapo JD, McClellan RO. (eds). Toxicology of the lung. Second edition. Target organ toxicology series (Hayes AW, Thomas JA, Gardner DE (Series eds). New York, Raven Press , 1993; pp. 461-85.
53.
Jepson GW, Hoover DK, Black RK, McCafferty JD, Mahle DA, Gearhart JMA partition coefficient determination method for nonvolatile chemicals in biological tissues. Fundamental and Applied Toxicology1994; 22: 519-24.
54.
Pacifici GM , Viani A.Methods of determining plasma and tissue binding of drugs. Clinical Pharmacokinetics1992; 23: 449-68.
55.
Hildebrand RL, Andersen ME, Jenkins LJPrediction of in vivo kinetic constants from kinetic constants measured in vitro. Fundamental and Applied Toxicology1981; 1 : 403-9.
56.
Houston JBRelevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics . Toxicology in vitro1994; 8: 507-12.
57.
Kedderis GL , Carfagna MA, Held SD, Batra R., Murphy JE and Gargas MLKinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro. Toxicology and Applied Pharmacology1993; 123 : 274-82.
58.
Johanson G.Use to Toxicokinetics in risk assessment based on in vitro data. ATLA1993; 21: 173-80.
59.
Lam CW, Galen TJ, Boyd JF, Pierson DLMechanisms of transport of organic solvents in blood. Toxicology and Applied Pharmacology1990; 104: 117-29.
60.
Overton JHRespiratory tract physiological processes and the uptake of gases . In: Gerrity TR, Henry CJ. (eds). Principles of route-to-route extrapolation for risk assessment. New York , Elsevier, 1990; pp. 71-91.
61.
Overton JHA respiratory tract dosimetry model for air toxics. Toxicology and Industrial Health1990; 6: 171-80.
62.
Andersen ME , Clewell HJ, Gargas ML, Smith FA, Reitz RHPhysiologically based pharmacokinetics and the risk assessment process for methylene chloride . Toxicology and Applied Pharmacology1987; 87: 185-205.
63.
Oreskes N., Shrader-Frechette K., Belitz K.Verification, validation, and confirmation of numerical models in the earth sciences. Science1994; 263: 641-6.
64.
Leung HWDevelopment and utilization of physiologically based pharmacokinetic models of toxicological applications. Journal of Toxicology and Environmental Health1991; 32: 247-67.
65.
Reitz RH, Mendrela AL, Park CN, Andersen ME, Guengerich FPIncorporation of in vitro enzyme data into the physiologically based pharmacokinetic (PB-PK) model for methylene chloride: implications for risk assessment. Toxicology Letters1988 ; 43: 97-116.
66.
Reitz RH, Mendrela AL, Guengerich FPIn vitro metabolism of methylene chloride in human and animal tissues: use in physiologically based pharmacokinetic models. Toxicology and Applied Pharmacology1989; 97: 230-46.
67.
Frederick CB , Potter DW, Chang-Mateu MI, Andersen MEA physiologically based pharmacokinetic and pharmacodynamic model to describe the oral dosing of rats with ethyl acrylate and its implications for risk assessment. Toxicology and Applied Pharmacology1992; 114: 246-60.
68.
El-Masri HA , Thomas RS, Benjamin SA, Yang Rsh.Physiologically based pharmacokinetic/ pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment. Toxicology1995 ; 105: 275-82.
69.
Mehendale HMMechanism of the interactive amplification of halomethane hepatotoxicity and lethality by other chemicals. In: Yang RSH. (ed). Toxicology of Chemical Mixtures: Case Studies, Mechanisms, and Novel Approaches . San Diego, CA, Academic Press1994; pp. 299-334.
70.
Lockard VG, Mehendale HM, O'Neal RMChlordecone-induced potentiation of carbon tetrachloride hepatotoxicity: A morphometric and biochemical study. Experimental Molecular Pathology1983; 39 : 246-55.
71.
Jarabek AM, Menache MG, Overton JH Jr, Dourson ML, Miller FJThe US Environmental Protection Agency's inhalation RfD methodology: risk assessment for air toxics. Toxicology and Industrial Health1990; 6: 279-301.
72.
Portier CJ, Kaplan NLVariability of safe dose estimates when using complicated models of the carcinogenic process. Fundamental and Applied Toxicology1989; 13 : 533-44.
73.
Slob W., Krajnc EIInterindividual variability in modeling exposure and toxicokinetics: a case study on cadmium. Environmental Health Perspectives1994; 102, 78 - 81.
